Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
D1000078 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition |
| 2 | EXPERIMENTAL | D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition |
| 3 | EXPERIMENTAL | D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition |
| 4 | EXPERIMENTAL | D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition |
| 5 | EXPERIMENTAL | D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition |
| 6 | EXPERIMENTAL | D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition |
| Name | Type | Description |
|---|---|---|
| D1000078 | DRUG | Oral, one single dose |
| D1000082 | DRUG | Oral, one single dose |
| D1000083 | DRUG | Oral, one single dose |
| D1000085 | DRUG | Oral, one single dose |
Inclusion Criteria: * Ethnic origin: Caucasian * Body-mass index (BMI): ≥ 19 kg/m² and ≤ 27 kg/m² * Good health * Written informed consent, after having been informed about benefits and potential risks of the trial Exclusion Criteria: * Diseases which could influence the gastric emptying and gast...
D1000078 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for gastric emptying time, a gastrointestinal measurement. It has been studied in a Phase 1 clinical trial. It is not an approved medicine and remains in clinical development.
D1000078 was studied for gastric emptying time, the rate at which the stomach empties its contents, which falls within the gastrointestinal therapeutic area. The research used magnetic marker monitoring to assess gastrointestinal transport. It is investigational and has not been approved for any use.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of D1000078. The company sponsored the clinical research conducted on this small molecule asset in the gastrointestinal therapeutic area.
D1000078 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA or any other regulatory agency.
D1000078 has been evaluated in one completed Phase 1 trial, NCT01224587, titled Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions. It enrolled 5 healthy male volunteers aged 18 years and older in Germany and used a controlled, randomized design without double blinding.
The completed Phase 1 trial NCT01224587 assessed gastric emptying time along with small intestinal transit time, time for colon arrival, and food effect using magnetic marker monitoring. It enrolled 5 healthy male volunteers in Germany under fasting and fed conditions. The study is complete and no further trials are listed.